Core Insights - IGI Therapeutics SA and AbbVie Inc. have entered into an exclusive licensing agreement for IGI's investigational asset ISB 2001, aimed at oncology and autoimmune diseases [1][2] - AbbVie will have exclusive rights to develop, manufacture, and commercialize ISB 2001 in North America, Europe, Japan, and Greater China [2] Financial Terms - IGI will receive an upfront payment of $700 million and is eligible for up to $1.225 billion in milestone payments, along with tiered, double-digit royalties on net sales [3] - The total potential financial benefit for IGI from this agreement could reach $1.925 billion [3] Product Details - ISB 2001 is a first-in-class trispecific T-cell engager targeting BCMA and CD38 on myeloma cells and CD3 on T cells, currently in Phase 1 for relapsed/refractory multiple myeloma [3] - Recent data from a study presented at the 2025 ASCO Annual Meeting showed a sustained overall response rate (ORR) of 79% and a complete/stringent complete response (CR/sCR) rate of 30% in heavily pretreated relapsed/refractory myeloma patients [4] Regulatory Status - The U.S. FDA granted ISB 2001 Orphan Drug Designation in July 2023 and Fast Track Designation for relapsed/refractory myeloma patients in May 2025 [5] Market Context - Other companies in the industry are also pursuing significant partnerships, such as AstraZeneca's reported talks with Summit Therapeutics for a $15 billion deal and BioNTech's agreement with Bristol Myers Squibb involving $1.5 billion upfront [5][6] - AbbVie’s stock price increased by 2.63% to $195.63 following the announcement [7]

Core Viewpoint - IGI Therapeutics and AbbVie have entered into an exclusive licensing agreement for ISB 2001, a novel trispecific T-cell engager targeting multiple myeloma, which is currently in Phase 1 clinical trials [1][2]. Company Overview - IGI Therapeutics is a clinical-stage biotechnology company focused on developing innovative biologics in oncology, utilizing its proprietary BEAT® technology platform to create first-in-class multispecific therapies [7]. - AbbVie is a global biopharmaceutical company dedicated to discovering and delivering innovative medicines across various therapeutic areas, including oncology [8]. Product Details - ISB 2001 is designed to target BCMA and CD38 on myeloma cells and CD3 on T cells, aiming to improve safety and efficacy compared to first-generation bispecific antibodies [3]. - The drug has shown a sustained overall response rate (ORR) of 79% and a complete/stringent complete response (CR/sCR) rate of 30% in a heavily pretreated patient population [3]. Licensing Agreement - Under the agreement, AbbVie will have exclusive rights to develop, manufacture, and commercialize ISB 2001 in North America, Europe, Japan, and Greater China [2]. - IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in milestone payments, along with tiered, double-digit royalties on net sales [2]. Regulatory Designations - ISB 2001 received Orphan Drug Designation from the U.S. FDA in July 2023 and Fast Track Designation for treating relapsed/refractory myeloma patients in May 2025 [4]. BEAT® Platform - The BEAT® platform enables the development of next-generation immune cell engagers with enhanced stability and function, addressing limitations of traditional bispecific antibody production [5]. - Key features include multispecific versatility, optimized engineering for precise modulation, and robust manufacturability [5].